Parsaclisib
- Generic Name
- Parsaclisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22ClFN6O2
- CAS Number
- 1426698-88-5
- Unique Ingredient Identifier
- OS7097575K
- Background
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
- Associated Conditions
- -
- Associated Therapies
- -
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT02559492
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT02265510
- Locations
- 🇺🇸
Site 2, Nashville, Tennessee, United States
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT02018861
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath